文献速递类风湿关节炎

生物制剂与靶向合成DMARDs对类风湿关节炎患者报告结局的影响:系统综述与网状Meta分析

Effects of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcome domains in rheumatoid arthritis: a systematic review and network meta-analyses.
PubMed 文献 · RMD Open · 2026-06-24

该系统综述与网状Meta分析纳入99项随机对照试验,评估b/tsDMARDs对RA患者疼痛、疲劳、活动受限及身心健康的相对效应。JAK抑制剂和IL-6抑制剂在改善活动受限方面显著优于TNF抑制剂,利妥昔单抗总体排名最佳,IL-6抑制剂在心理健康领域排名最高。早期RA和基线PRO评分较差与更大改善相关。

要点

  • JAK抑制剂和IL-6抑制剂改善活动受限显著优于TNF抑制剂。
  • 利妥昔单抗总体排名最佳,IL-6抑制剂心理健康领域排名最高。
  • 早期RA(诊断<3年)和基线PRO评分较差者PRO改善更大。

核心结论

  • 尽管存在异质性,b/tsDMARDs对PROs的相对效应可为风湿科医生选择药物提供参考。

研究设计与样本

  • 系统综述与网状Meta分析,使用机器学习工具ASReview进行文献检索,纳入99项随机对照试验。
  • 纳入比较DMARDs与安慰剂或其他DMARDs并报告ICHOM标准集PROs的随机对照试验。
  • 对PROs进行随机效应网状Meta分析,比较间异质性I²范围为0%-96%。

主要发现

  • JAK抑制剂(MD HAQ:-0.13;95%CI -0.23至-0.04)和IL-6抑制剂(MD:-0.13;95%CI -0.27至-0.00)在减少活动受限方面显著优于TNF抑制剂。
  • 未观察到b/tsDMARDs类别间其他显著差异。
  • 累积排名曲线下面积显示利妥昔单抗在b/tsDMARDs中总体排名最佳。
  • IL-6抑制剂在心理健康领域排名最高(82%)。
  • 早期RA(诊断<3年)和基线PRO评分较差与PROs更大改善相关(p<0.05)。

关键数值与推荐

  • JAK抑制剂改善活动受限的MD(HAQ)为-0.13(95%CI -0.23至-0.04),优于TNF抑制剂。
  • IL-6抑制剂改善活动受限的MD为-0.13(95%CI -0.27至-0.00),优于TNF抑制剂。
  • IL-6抑制剂在心理健康领域的累积排名概率为82%。
  • 早期RA定义为诊断<3年,与PROs更大改善相关(p<0.05)。

临床怎么用

  • 选择b/tsDMARDs时可考虑患者重要的PROs或反映其主要症状的领域。
  • 对于活动受限突出的患者,JAK抑制剂或IL-6抑制剂可能优于TNF抑制剂。
  • 早期RA和基线PRO评分较差的患者可能从b/tsDMARDs中获得更大PRO改善。

局限性

  • 比较间异质性范围从低到非常高(I²=0%-96%)。
  • 未来需研究特定b/tsDMARDs的类别内差异,并强调在达标治疗策略中基于PRO的个体化增强。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Evidence from head-to-head comparisons of biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) is lacking. This systematic review and network meta-analysis (NMA) aims to evaluate the relative effects of b/tsDMARDs on the International Consortium for Health Outcomes Measurement (ICHOM) RA-relevant domains of pain, fatigue, activity limitation, and physical and mental health. METHODS: A systematic literature search was conducted using the machine learning tool ASReview. Randomised controlled trials were included that compared DMARDs with placebo or other DMARDs and reported the effects on PROs from the ICHOM standard set for inflammatory arthritis. Random effects NMA were performed on PROs. RESULTS: In total, 99 studies were included, with heterogeneity within comparisons ranging from low to very high (I²=0%-96%). Janus kinase inhibitors (mean difference (MD) Health Assessment Questionnaire: -0.13; 95% CI-0.23 to -0.04) and IL-6 inhibitors (MD: -0.13; 95% CI -0.27 to -0.00) were significantly better at reducing activity limitation than tumour necrosis factor inhibitors. Other significant differences between b/tsDMARD classes were not observed. The surface under the cumulative ranking curve demonstrated that rituximab was overall ranked best among b/tsDMARDs. IL-6 inhibitors ranked highest in the mental health domain (82%). Early RA (<3 years diagnosis) and worse baseline PRO scores were associated with larger improvements of PROs (p<0.05). CONCLUSIONS: Despite heterogeneity, the results of this study may help rheumatologists guide selection of b/tsDMARDs, taking into account PROs that are important to the patient or reflect their primary symptoms. Future research should investigate within-class differences between specific b/tsDMARDs and emphasise individualised, PRO-based augmentation within treat-to-target strategies. PROSPERO REGISTRATION NUMBER: CRD42020147514.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. van Esveld L, Dikkenberg MVD, Luurssen-Masurel N, et al. Effects of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcome domains in rheumatoid arthritis: a systematic review and network meta-analyses. RMD Open. 2026. PMID: 42342282. doi:10.1136/rmdopen-2025-006578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。